Close
Help





JOURNAL

Advances in Tumor Virology

Epstein-Barr Virus (EBV) and the Effectiveness of Suberoylanilide Hydroxamic Acid (SAHA) as a Treatment for EBV Infection and Associated Cancers

Submit a Paper


Advances in Tumor Virology 2013:3 1-7

Review

Published on 13 Oct 2013

DOI: 10.4137/ATV.S12242


Further metadata provided in PDF



Sign up for email alerts to receive notifications of new articles published in Advances in Tumor Virology

Abstract

Since being discovered in 1964, Epstein-Barr virus (EBV) has become a growing concern. Clinically, EBV is responsible for many diseases, most notably infectious mononucleosis. In addition to mononucleosis, EBV causes several cancers such as Hodgkin’s lymphoma, Burkitt’s lymphoma, and nasopharyngeal carcinoma (NPC). Suberoylanilide hydroxamic acid (SAHA) is an anti-cancer drug that inhibits growth and proliferation of various EBV-related cancers. SAHA acts as a histone deacetylase (HDAC) inhibitor. The responsiveness of SAHA treatment stems from the induction of EBV’s lytic cycle.



Downloads

PDF  (577.27 KB PDF FORMAT)

RIS citation   (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)

BibTex citation   (BIBDESK, LATEX)





Quick Links


New article and journal news notification services